All News

computer.health.jpg (keep)

EULAR Best Abstracts - Day 2

d Jack Cush, MD

The second day of EULAR 2021 took a big leap in online content.  #EULAR2021 generated 2500 tweets yesterday. Here is a compilation (with links) of presentations were the “Best” as seen by our RheumNow faculty. 

Read Article
grappa sign treatment recommendations

New GRAPPA 2021 PsO and PsA Treatment Recommendations

d Rachel Tate, DO

The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021.

Read Article
Lupus.right_.jpg

Is Rituximab and Belimumab the Combination to Beat Lupus?

d Eric Dein, MD

On day 2 of EULAR conference, Dr. Michael Ehrenstein presented OP0129, a presentation on the BEAT-LUPUS trial looking at belimumab therapy after rituximab. B cell depletion with rituximab is common treatment for refractory SLE, though real-world data for rituximab has been uncertain. It is known that B-cell activating factor (BAFF) levels can increase after rituximab, which can lead to disease flares. Using belimumab, a human monoclonal antibody inhibiting BAFF, could be a potential therapeutic option after rituximab infusions. 

Read Article
acr_session2.jpeg

EULAR 2021 – Day 2 Report

d Jack Cush, MD

During Day 2 there were great sessions devoted to RA, spondylarthritis, fatigue and more.  Here are some of my highlights from Day 2.

Read Article
Guselkumab in patients with active #Psoriatic_Arthritis & who failed anti-TNF: COSMOS study Phase 3b A new option for the difficult-to-treat patients with PsA @DrLauraCoates #EULAR2021 https://t.co/2aOqZYfbsT
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Upacitinib in #Psoriatic_Arthritis with axial manifestations Post hoc analysis from SELECT PsA1/2 #EULAR2021 @deodhara https://t.co/867c2J3DiI
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Very interesting 🤔 talk about the role of #comorbidities in difficult to treat #RA by our fabulous #emeunet past chair @ElenaNikiUK at #EULAR2021 @eular_org https://t.co/zyQ0DkKhbu
EMEUNET EMEUNET ( View Tweet)
NEW RESEARCH—Safety and efficacy of #rituximab in #SystemicSclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial https://t.co/Sb3d1kPhL4 #LancetRheumatology https://t.co/4SMVGY0C3M

Links:

The Lancet Rheumatology TheLancetRheum ( View Tweet)
Potential new player on the block, B-cell associated cytokine IL-40 in #Sjogren. Dr Rizzo showed ⬆️IL40 expression in salivary gland biopsy & bloods in pSS and pSS-associated lymphoma. Future work will clarify the exact role of IL-40 as a tx target #EULAR2021 #POS0177 @RheumNow https://t.co/uXAYAlkdtD
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)

⭐️Deucravacitnib = oral TYK2i w/ downstream inhibitory effects on IL23, IL12 & type I IFN pathways ⭐️Recent studies (POETYK PSO-1/2) show that it outperforms Otezla per PASI75 ⭐️OP0227 shows it is also efficacious for active PsA vs PBO w/ no serious AEs #EULAR2021 @Rheumnow https://t.co/qA1NsLzQsF

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Does #baricitinib affect B-cell activity in #SLE?Dr Dorner reported in patients with dsDNA ab+ve (=>30iU/mL), Bari 4mg reduced dsDNA,anti-Sm, cardiolipin and IgG at Wk24 vs placebo. In pts who dsDNA normalised, their SRI-4 was no different vs dsDNA+ #EULAR2021 #POS0686 @RheumNow https://t.co/pmNWEE9hqg
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
OP0227: Efficacy of Deucravactinib for PsA? ⭐️Deucrav = TYK2i. ⭐️Dr. Mease et al show MDA by wk16 + stat. signif improv in ACR20/50/70, enthes, & dactyl w/ deucrav vs PBO in pts w/ active PsA. ⭐️Incl crit: failed at least 1 csDMARD/NSAID/GC & up to 1 TNFi #EULAR2021 @Rheumnow https://t.co/1jjsZIODFV
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#SLE and #Sjogren: is there a path for these to converge? Dr Martin-Guttierez used #MachineLearning to analyse blood & identified 2 endotypes. Both had different trajectory in disease activity & damage. May be useful to stratify appropriate therapy #EULAR2021 #POS0174 @RheumNow https://t.co/R4NMDJYVbY
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Better pics re JAKi retention better than bDMARDs in RA. But single site, ? Selection bias. Curves spread after 1st yr of Rx. Findings same if only 1st line adv Rx or adjusted for line of therapy POS0205 #EULAR2021 @RheumNow https://t.co/6HYpgVeyiw https://t.co/5mjpUFfWoG

Links:

Janet Pope Janetbirdope ( View Tweet)
Dr Eder reports population-based, matched cohort study 3 million people. IMID associated ⬆️ hospitalisation in COVID-19. OR 1.23, 95% CI 1.10, 1.37 @RheumNow #EULAR2021 Abstr#OP0285 https://t.co/KDK5j1Gg0X
Richard Conway RichardPAConway ( View Tweet)
Dr. Laura Coates discusses "what is fatigue" based on clinical outcome and disease activity measures in PsA. Three main groups stood out in predicting fatigue in these patients: level of inflammation, chronic pain, and chronicity of PsA disease. #EULAR2021 @RheumNow https://t.co/pFYRb1X7pT
Dr. Rachel Tate uptoTate ( View Tweet)

RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, and Janssen. All content chosen by RheumNow and its faculty.

Dr. John Cush RheumNow ( View Tweet)

Check out our Lupus coverage from #EULAR2021 https://t.co/Gmh4sFv4Jl https://t.co/OihiiomZBd

Links:

Dr. John Cush RheumNow ( View Tweet)
#EULAR2021 How to Measure Success in Lupus? Dr. Kathryn Dao ( @KDAO2011 ) https://t.co/z8c8moIQCa https://t.co/0BLeFJyZD4

Links:

Dr. John Cush RheumNow ( View Tweet)
What's your EULAR IQ? Test your knowledge! #EULAR2021 https://t.co/psumBpzUc7 https://t.co/w5Vg68RVLs

Links:

Dr. John Cush RheumNow ( View Tweet)
×